i-RNA Corporation

Profile

i-RNA Corporation is a Canadian preclinical biotech developing small interfering RNA (siRNA) therapeutics for diabetic retinopathy, a leading cause of global blindness. The company’s approach targets HOX transcript antisense intergenic RNA (HOTAIR), a long non-coding RNA that regulates disease-driving pathways, including angiogenesis, inflammation, and oxidative stress, and key proteins including vascular endothelial growth factor (VEGF), enabling broader disease-modifying potential beyond current standards of care. Its modified siRNA molecules have demonstrated robust efficacy in preclinical models, including a lead candidate designed for topical delivery as an eye drop, offering a safer, patient-friendly alternative to intravitreal anti-VEGF injections and improving treatment accessibility and patient compliance.

Website

i-rna.ca

Contact


Event details

Date: October 7 - 9, 2026

Event contact

Stephen Ip
Senior International Market Consultant
Japan and Korea

Participants

<?php global $lang_id; switch ($lang_id) { case "fr": echo 'Total de 13'; break; case "pt-br": echo 'Total de 13'; break; case "es": echo 'Total de 13'; break; case "ja": echo '13 合計'; break; case "ko": echo '13 총계'; break; case "en": default: echo '13 in total'; break; } ?>